India's Shilpa Medicare to produce Cadila's COVID-19 shot
The Peninsula
BENGALURU - Indian drugmaker Shilpa Medicare Limited said on Friday it had agreed to produce Cadila Healthcare Ltd's three-dose COVID-19 vaccine.
The country's health authorities had given emergency approval in August for Cadila's vaccine, the world's first COVID-19 DNA shot, in adults and children aged 12 years and above.
Cadila, which is expected to begin supplying its vaccine from next month, aims to make 100 million to 120 million doses of ZyCoV-D a year.
More Related News